GE HealthCare Introduces Vscan Air SL, a Wireless Handheld Ultrasound Device for Rapid Assessments of Cardiac and Vascular Patients

With a dual-headed probe, the Vscan Air SL offers a sector array and a linear array on a single device which is ideal for switching between focused cardiac assessments and vascular assessments right at the point of care – both inside and outside of the hospital. Vscan Air SL is the newest addition to the Vscan product suite, which includes more than 50,000 systems in the pockets of clinicians, impacting the care of more than an estimated 100 million patients worldwide.

GE HealthCare (Nasdaq: GEHC) today announced the launch of Vscan Air SL – a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions. The latest addition to the Vscan product suite, Vscan Air SL features GE HealthCare’s proprietary SignalMax and XDclear technology that provide high levels of penetration, resolution, and sensitivity in imaging performance with an industry-leading single crystal transducer technology.

With cardiovascular disease the most prevalent disease worldwide1 often presenting in emergency situations, prompt diagnosis and treatment can be vital. The portable, wireless Vscan Air SL is designed to enable clinicians to efficiently collect and view crystal clear cardiac and vascular images at the point of care. By streamlining these workflows and avoiding overloading traditional radiology resources, clinicians can expedite care decisions to help patients receive treatment plans right away when time is of the essence.

“Having ever more powerful handheld ultrasound is a game changer for patient care,” said Guy Lloyd, M.D., FRCP, consultant cardiologist at Barts Heart Center, University College London Hospitals and clinical director for Cardiovascular Diagnostics and Investigations. “Whether on the ward or in general practice, being able to provide high-quality imaging at the point of care means rapid diagnosis and rapid treatment.”

With Vscan Air SL, clinicians have a pocket-sized, portable tool that allows for clear, whole-body scanning and secure viewing of images. In addition, through Vscan Air + Digital Tools, clinicians have access to subscriptions that can connect them to a suite of easy-to-use solutions designed to improve workflow with secure collaboration, image, and device management features.

“Vscan Air SL enables clinicians to make quick cardiac assessments and adds to our broad portfolio of ultrasound technologies to help further inform clinical decision making at the point of care,” said Dietmar Seifriedsberger, Global General Manager, Point of Care and Handheld Ultrasound at GE HealthCare. “This newest innovation demonstrates our commitment to providing integrated solutions resulting in better standard of care delivery — and ultimately helping clinicians improve patient outcomes.”

GE HealthCare pioneered the first color pocket-sized ultrasound, Vscan, in 2010 and has since continued to revolutionize the way clinicians treat patients. In 2021, GE HealthCare introduced one of the smallest and most lightweight handheld ultrasound devices with the Vscan Air CL. To date, there are more than 50,000 systems from the Vscan product suite in the pockets of clinicians, impacting the care of more than an estimated 100 million patients worldwide.2 Vscan Air CL and SL continue the company’s commitment to innovation and transforming the clinical exam by making it easier to acquire high quality ultrasound images.

GE HealthCare is showcasing Vscan Air SL at the European Society of Cardiology (ESC) 2023 annual meeting in Amsterdam, Netherlands Friday, August 25 – Monday, August 28 in booth #H500. The booth features the theme “Know. Now.” with information and resources to raise awareness of the importance of early detection of cardiovascular disease for better patient outcomes.

Vscan Air SL is currently commercially available in key countries throughout Europe and Asia as well as Australia and New Zealand. In the United States, Vscan Air SL is 510(k) cleared by the U.S. Food and Drug Administration and will become commercially available this quarter.

For more information about the GE HealthCare Vscan Air wireless handheld ultrasound, please visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version